SELUTION DeNovo: Sirolimus DCB Safe and Effective in ACS Patients

Why It Matters

The data validate a minimal‑stent approach for ACS, offering clinicians a safe alternative that could reduce long‑term metal burden and procedural costs. Demonstrated safety and efficacy may accelerate regulatory acceptance and shift interventional cardiology practice patterns.

Key Takeaways

• Selution sirolimus DCB showed 5.3% TVF vs 4.9% with DES.
• Bailout stenting occurred in 18% of DCB patients, decreasing after learning curve.
• No difference observed in acute or late lesion thrombosis between strategies.
• European CE mark approved DCB; US cost may limit widespread use.

Pulse Analysis

The SELUTION DeNovo trial adds a pivotal chapter to the evolving story of drug‑coated balloons in coronary interventions. While drug‑eluting stents have dominated ACS treatment for decades, the sirolimus‑eluting Selution balloon offers a “leave‑nothing‑behind” alternative that matches DES performance at one year. By targeting lesions 2‑5 mm and employing provisional stenting only when necessary, the DCB reduces permanent metal implantation, potentially lowering chronic inflammation and facilitating future re‑interventions. The trial’s robust sample—over 1,000 ACS patients—provides clinicians with confidence that the balloon’s efficacy extends beyond stable coronary disease.

A notable finding is the modest bailout stenting rate of 18% in the DCB arm, which fell after operators completed roughly 25 cases, underscoring the importance of experience with balloon deployment and lesion preparation. Importantly, the study reported no increase in acute or late thrombosis, all‑cause mortality, stroke, or major bleeding compared with DES, alleviating long‑standing concerns about thrombus‑laden vessels. These safety signals, combined with comparable TVF outcomes, suggest that a minimal‑stent strategy can be safely applied to NSTEMI and unstable angina patients, expanding the therapeutic toolbox for interventional cardiologists.

From a market perspective, the DCB enjoys CE‑Mark clearance in Europe and has begun to reshape practice patterns there, yet U.S. adoption faces price sensitivity. At current U.S. pricing, hospitals demand clear, long‑term cost‑effectiveness data before replacing DES with a more expensive balloon. Ongoing five‑year follow‑up will be critical to demonstrate any late‑stage advantage, such as reduced restenosis or lower repeat revascularization rates. If those benefits materialize, the Selution DCB could challenge the DES monopoly, prompting insurers and providers to reconsider reimbursement models and potentially driving broader diffusion of drug‑coated balloon technology in the United States.